Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central anxious system, conolidine modulates alternate molecular targets. A Science Improvements review located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://eleanorw208yab9.idblogz.com/profile